FrancophonIA/ELRC3.0 huggingface dataset:
English: Your doctor will tell you whether this is the case, based on the results of your last blood test; →Tell your doctor if you think any of these could apply to you.
Croatian: Liječnik će zaključiti da je li to slučaj na temelju posljednjih nalaza krvnih pretraga.
English: In patients (n = 39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95 % CI: 2,6, 6.1) versus 4.5 months (95 % CI: 2.9, 9.6) for the cisplatin arm with a hazard ratio of 1.15 (0.59, 2.23).
Croatian: U bolesnica (n = 39) s recidivom unutar 180 dana nakon kemoradioterapije cisplatinom, medijan preživljenja u skupini liječenoj kombinacijom topotekana i cisplatina iznosio je 4,6 mjeseci (95% CI: 2,6; 6,1), u usporedbi s 4,5 mjeseca (95% CI: 2,9; 9,6) u skupini liječenoj cisplatinom, uz omjer hazarda od 1,15 (0,59; 2,23).
English: Haematological
Croatian: Hematološke
English: What you need to know before you use Topotecan Teva Do not use Topotecan Teva:
Croatian: Što morate znati prije nego počnete primjenjivati Topotekan Teva
English: Decrease in the number of all blood cells (pancytopenia ) Allergic or hypersensitivity reactions (including rash).
Croatian: - Alergijske reakcije ili reakcije preosjetljivosti (uključujući osip).
English: Resulting from its mechanism of action, topotecan is genotoxic to mammalian cells (mouse lymphoma cells and human lymphocytes) in vitro and mouse bone marrow cells in vivo.
Croatian: 5.3 Neklinički podaci o sigurnosti primjene Zbog mehanizma djelovanja, topotekan je genotoksičan za stanice sisavaca (stanice mišjeg limfoma i ljudske limfocite) in vitro i za stanice mišje koštane srži in vivo.
English: Read the package leaflet before use.
Croatian: Pripremiti prije uporabe.
English: The use of Topotecan Teva is not recommended in patients with severe renal impairment; if you have liver problems.
Croatian: Primjena lijeka Topotekan Teva ne preporučuje se bolesnicima s teškim oštećenjem funkcije bubrega.
English: Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Croatian: Topotekan se ne smije ponovno primijeniti ukoliko broj neutrofila nije ≥ 1 x 109/1, broj trombocita ≥ 100 x 109/1 i razina hemoglobina ≥ 9 g/d1 (nakon transfuzije, ukoliko je potrebna).
English: There is insufficient experience of the use of topotecan in patients with severely impaired renal function (creatinine clearance < 20 ml/min) or severely impaired hepatic function (serum bilirubin ≥ 10 mg/dl) due to cirrhosis.
Croatian: Nema dovoljno iskustva s primjenom topotekana u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina <20 ml/min) ili teškim oštećenjem jetrene funkcije zbog ciroze (vrijednost bilirubina u serumu 10 mg/dl ili više).
English: Rare (may affect up to 1 in 1,000 people)
Croatian: Rijetke nuspojave (mogu se javiti do 1 na 1000 osoba)
English: Topotecan monotherapy is indicated for the treatment of: patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy.
Croatian: • bolesnica s metastatskim karcinomom jajnika nakon neuspjeha prve i naknadnih linija liječenja
English: Women of childbearing potential / Contraception in males and females Topotecan has been shown to cause embryo-foetal lethality and malformations in preclinical studies (see section 5.3).
Croatian: Pretklinička ispitivanja su pokazala da topotekan uzrokuje smrt i malformacije embrija i fetusa (vidjeti dio 5.3).
English: There is insufficient experience with the use of topotecan in patients with severely impaired hepatic function (serum bilirubin ≥ 10 mg/dl) due to cirrhosis.
Croatian: Nema dovoljno iskustva s primjenom topotekana u bolesnika s teškim oštećenjem jetrene funkcije zbog ciroze (vrijednost bilirubina u serumu ≥ 10 mg/dl).
English: Very rare
Croatian: Često svrbež
English: fever serious decline of your general condition local symptoms such as sore throat or burning sensation when urinating severe stomach pain, fever and possibly diarrhoea (rarely with blood) can be signs of bowel inflammation (neutropenic colitis).
Croatian: - vrućica - ozbiljno pogoršanje općeg stanja - lokalni simptomi kao što su grlobolja ili osjećaj pečenja pri mokrenju - jaka bol u trbuhu, vrućica i moguće i proljev (rijetko krvavi) mogu biti znakovi upale crijeva (neutropeničnog kolitisa).
English: When topotecan (0.75 mg/m2/day for 5 consecutive days) and cisplatin (60 mg/m2/day on day 1) were administered in 13 patients with ovarian cancer, a slight increase in AUC (12%, n = 9) and Cmax (23%, n = 11) was noted on day 5.
Croatian: Prilikom primjene topotekana (0,75 mg/m2/dan tijekom 5 uzastopnih dana) i cisplatina (60 mg/m2/dan 1. dana) u 13 bolesnica s karcinomom jajnika, 5. dan je zabilježen blagi porast vrijednosti AUC-a
English: Topotecan should not be re-administered unless the neutrophil count is ≥ 1.5 x 109/l, the platelet count is ≥100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Croatian: Topotekan se ne smije ponovno primijeniti ukoliko broj neutrofila nije ≥ 1,5 x 109/1, broj trombocita ≥ 100 x 109/1 i razina hemoglobina ≥ 9 g/d1 (nakon transfuzije, ukoliko je potrebna).
English: Skin and subcutaneous tissue disorders
Croatian: Poremećaji kože i potkožnog tkiva Vrlo često alopecija
English: Storage of the diluted solution
Croatian: Čuvanje razrijeđene otopine
English: Concentrate for solution for infusion 1 vial of 4 ml (4 mg topotecan) 5 vials of 4 ml (4 mg topotecan)
Croatian: 1 bočica od 4 ml (4 mg topotekana) 5 bočica od 4 ml (4 mg topotekana)
English: Concentrate for solution for infusion 1 vial of 1 ml (1 mg topotecan) 5 vials of 1 ml (1 mg topotecan)
Croatian: 1 bočica od 1 ml (1 mg topotekana) 5 bočica od 1 ml (1 mg topotekana)
English: Each vial contains 1 ml of the concentrate for solution for infusion.
Croatian: Jedna bočica sadrži 1 ml koncentrata za otopinu za infuziju.
English: Topotecan Teva 1 mg/1 ml concentrate for solution for infusion Topotecan Teva 4 mg/4 ml concentrate for solution for infusion
Croatian: Topotekan Teva 1 mg/1 ml koncentrat za otopinu za infuziju Topotekan Teva 4 mg/4 ml koncentrat za otopinu za infuziju
English: Fatalities due to neutropenic colitis have been reported in clinical studies with topotecan.
Croatian: U kliničkim ispitivanjima topotekana zabilježeni su slučajevi neutropeničnog kolitisa sa smrtnim ishodom.
English: The recommended dose of topotecan is 0.75 mg/m2/day administered as a 30-minute intravenous infusion on days 1, 2 and 3.
Croatian: Preporučena doza topotekana je 0,75 mg/m2/dan, primijenjena intravenskom infuzijom u trajanju od
English: One study included a dose range of 1.4 to 2.4 mg/m2 in children (aged 2 up to 12 years, n = 18), adolescents (aged 12 up to 16 years, n = 9) and young adults (aged 16 to 21 years, n = 9) with refractory solid tumours.
Croatian: 12 godina, n = 18), adolescenata (u dobi od 12-16 godina, n = 9) i mlađih odraslih osoba (u dobi od
English: Package leaflet: Information for the user Topotecan Teva 1 mg/1 ml concentrate for solution for infusion topotecan
Croatian: Uputa o lijeku: Informacije za korisnika Topotekan Teva 1 mg/1 ml koncentrat za otopinu za infuziju topotekan
English: In those patients (n = 102) with recurrence after 180 days, median survival in the topotecan plus cisplatin arm was 9.9 months (95 % CI: 7, 12.6) versus 6.3 months (95 % CI: 4.9, 9.5) for the cisplatin arm with a hazard ratio of 0.75 (0.49, 1.16).
Croatian: U bolesnica (n = 102) s recidivom nakon 180 dana, medijan preživljenja u skupini liječenoj kombinacijom topotekana i cisplatina iznosio je 9,9 mjeseci (95% CI: 7; 12,6), u odnosu na 6,3 mjeseca (95% CI: 4,9; 9,5) u skupini liječenoj cisplatinom, uz omjer hazarda od 0,75
English: 2 Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section 4.4).
Croatian: 2 Kao komplikacija neutropenije izazvane topotekanom prijavljen je neutropenijski kolitis, ponekad sa smrtnim ishodom (vidjeti dio 4.4).
English: Each vial contains 4 ml of the concentrate for solution for infusion.
Croatian: Jedna bočica sadrži 4 ml koncentrata za otopinu za infuziju.
English: Your dose of Topotecan Teva will depend on: the disease being treated your body surface area (m2) the results of blood tests carried out before and during treatment how well you tolerate treatment.
Croatian: - rezultatima krvnih pretraga koje se provode prije i tijekom liječenja - tome koliko dobro podnosite liječenje
English: How Topotecan Teva is prepared
Croatian: Kako se priprema Topotekan Teva
English: Median survivals for the two groups were 25.0 and 24.7 weeks respectively.
Croatian: Medijan vremena preživljenja iznosio je 25,0 za topotekan, odnosno 24,7 tjedana za CAV protokol.
English: How to store Topotecan Teva
Croatian: Kako čuvati Topotekan Teva
English: Common (may affect up to 1 in 10 people)
Croatian: Česte nuspojave (mogu se javiti do 1 na 10 osoba)
English: Package leaflet: Information for the user Topotecan Teva 4 mg/4 ml concentrate for solution for infusion topotecan
Croatian: Uputa o lijeku: Informacije za korisnika Topotekan Teva 4 mg/4 ml koncentrat za otopinu za infuziju topotekan
English: Extravasation3
Croatian: Vrlo rijetko ekstravazacija3
English: The elimination of topotecan has only been partly investigated in man. A major route of clearance of topotecan was by hydrolysis of the lactone ring to form the ring-opened carboxylate.
Croatian: Glavni put klirensa topotekana je hidroliza laktonskog prstena koja stvara karboksilat otvorenog prstena.
English: The normal procedures for proper handling and disposal of anticancer medicinal products should be adopted, namely:
Croatian: Potrebno je slijediti uobičajena pravila za ispravno rukovanje i odlaganje lijekova za liječenje karcinoma: - Osoblje mora biti educirano za razrjeđivanje lijeka.
English: Non-haematological
Croatian: Nehematološke
English: Topotecan Teva 4 mg/4 ml concentrate for solution for infusion topotecan
Croatian: Topotekan Teva 4 mg/4 ml koncentrat za otopinu za infuziju topotekan
English: Topotecan Teva 1 mg/1 ml concentrate for solution for infusion 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
Croatian: Topotekan Teva 1 mg/1 ml koncentrat za otopinu za infuziju 1 ml koncentrata za otopinu za infuziju sadrži 1 mg topotekana (u obliku topotekanklorida).
English: Sepsis1
Croatian: Često sepsa1
English: The prescribing information for cisplatin should be consulted for a full list of adverse events associated with cisplatin use.
Croatian: Za cjeloviti popis štetnih događaja povezanih s liječenjem cisplatinom potrebno je proučiti upute za propisivanje cisplatina.
English: Each vial contains 4 mg topotecan (as hydrochloride) in 4 ml concentrate.
Croatian: Jedna bočica sadrži 4 mg topotekana (u obliku topotekanklorida) u 4 ml koncentrata.
English: Topotecan Teva 4 mg/4 ml concentrate for solution for infusion 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
Croatian: Topotekan Teva 4 mg/4 ml koncentrat za otopinu za infuziju 1 ml koncentrata za otopinu za infuziju sadrži 1 mg topotekana (u obliku topotekanklorida).
English: if you are allergic to topotecan or any of the other ingredients of this medicine (listed in section if you are breast-feeding; if your blood cells count is too low.
Croatian: • ako ste alergični na topotekan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6);
English: • Lung inflammation (rare (may affect up to 1 in 1,000 people)), with signs such as: difficulty breathing, cough fever.
Croatian: Upala pluća (rijetko (mogu se javiti do 1 na 1000 osoba)), čiji znakovi uključuju:
English: Each vial contains 1 mg topotecan (as hydrochloride) in 1 ml concentrate.
Croatian: Jedna bočica sadrži 1 mg topotekana (u obliku topotekanklorida) u 1 ml koncentrata.
English: Very common Nausea, vomiting and diarrhoea (all of which may be severe), constipation, abdominal pain2, mucositis
Croatian: Rijetko intersticijska bolest pluća (neki slučajevi su imali smrtni ishod) Poremećaji probavnog sustava Vrlo često mučnina, povraćanje i proljev (svi mogu biti teški), konstipacija, bolovi u abdomenu2, mukozitis
English: Topotecan Teva 1 mg/1 ml concentrate for solution for infusion topotecan
Croatian: Topotekan Teva 1 mg/1ml koncentrat za otopinu za infuziju topotekan
English: How to use Topotecan Teva
Croatian: Kako primjenjivati Topotekan Teva
English: Additional adverse events were seen when topotecan was given in combination with cisplatin, however, these events were seen with cisplatin monotherapy and were not attributable to topotecan.
Croatian: međutim ti događaji bili su zabilježeni i u monoterapiji cisplatinom i nisu bili povezani s topotekanom.
English: Standard oncology practice for the management of neutropenia is either to administer topotecan with other medicinal products (e.g. G-CSF) or to reduce the dose to maintain neutrophil counts.
Croatian: Uobičajena onkološka praksa zbrinjavanja neutropenije je ili primjena topotekana s drugim lijekovima
English: A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10 mg/dl) were given intravenous topotecan at 1.5 mg/m2/day for five days every three weeks.
Croatian: 10 mg/dl) primio je topotekan intravenski u dozi od 1,5 mg/m²/dan tijekom pet dana svaka tri tjedna.
English: EU/1/09/552/001 - 1 vial EU/1/09/552/002 - 5 vials
Croatian: EU/1/09/552/001 - 1 bočica EU/1/09/552/002 - 5 bočica
English: Hydrochloric acid (E507) (for pH adjustment) Sodium hydroxide (E524) (for pH adjustment) Water for injections
Croatian: 6.1 Popis pomoćnih tvari tartaratna kiselina (E334) kloridna kiselina (E507) (za podešavanje pH) natrijev hidroksid (E524) (za podešavanje pH) voda za injekcije
English: An O-glucuronidation metabolite of topotecan and Ndesmethyl topotecan has been identified in the urine.
Croatian: O-glukuronidacije topotekana i N-desmetiltopotekan.
English: EU/1/09/552/003 - 1 vial EU/1/09/552/004 - 5 vials
Croatian: EU/1/09/552/003 - 1 bočica EU/1/09/552/004 - 5 bočica
English: 1.5 mg/dl, it is recommended that the full prescribing information be consulted for any advice on cisplatin dose reduction/continuation.
Croatian: Ako se tijekom terapije kombinacijom topotekana i cisplatine vrijednost kreatinina u serumu poveća iznad 1,5 mg/dl, preporučuje se proučiti detaljne upute za propisivanje radi savjeta o smanjenju doze ili nastavku liječenja cisplatinom.
English: Tel: +39 028 917 981
Croatian: Teva Italia S.r.l. Tel: + 39 028 917 981
English: The incidence of severe (Grade 3 or 4) nausea, vomiting, diarrhoea and mucositis was 4, 3, 2 and 1 % respectively.
Croatian: (stupanj 3 ili 4) mučnine bila je 4%, povraćanja 3%, proljeva 2% i mukozitisa 1%.
English: EU/1/09/552/004- 5 vials
Croatian: EU/1/09/552/004 - 5 bočica
English: One vial of 1 ml of concentrate contains 1 mg topotecan (as hydrochloride).
Croatian: Jedna bočica od 1 ml koncentrata sadrži 1 mg topotekana (u obliku topotekanklorida).
English: One vial of 4 ml of concentrate contains 4 mg topotecan (as hydrochloride).
Croatian: Jedna bočica od 4 ml koncentrata sadrži 4 mg topotekana (u obliku topotekanklorida).
English: One vial of 4 ml of concentrate for solution for infusion contains 4 mg topotecan (as hydrochloride).
Croatian: Jedna bočica od 4 ml koncentrata za otopinu za infuziju sadrži 4 mg topotekana (u obliku topotekanklorida).
English: EU/1/09/552/002- 5 vials
Croatian: EU/1/09/552/002 - 5 bočica
English: 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
Croatian: 1 ml koncentrata za otopinu za infuziju sadrži 1 mg topotekana (u obliku topotekanklorida).
English: Study results Study GOG-0179 ITT population Cisplatin 50 mg/m2 on day 1, every 21 days
Croatian: 50 mg/m2 1. dana, svakih 21 dan cisplatin 50 mg/m2 1. dana
English: Plasma clearance in patients with renal impairment (creatinine clearance 41-60 ml/min.)
Croatian: Oštećenje jetre Klirens plazme u bolesnika s oštećenjem jetre (vrijednosti bilirubina u serumu između 1,5 i 10 mg/dl)
English: Vial before opening 30 months.
Croatian: Bočica prije otvaranja
English: A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Croatian: PRILOG II. A. PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: Median survival in patients treated with oral topotecan plus BSC was 25.9 weeks (95 % CI 18.3, 31.6) compared to 13.9 weeks (95 % CI 11.1, 18.6) for patients receiving BSC alone (p = 0.0104).
Croatian: Medijan vremena preživljenja bolesnika liječenih oralnim topotekanom plus BSC-om iznosio je 25,9 tjedana (95% CI: 18,3; 31,6) u usporedbi s 13,9
English: Very common Anorexia (which may be severe)
Croatian: Rijetko anafilaktička reakcija, angioedem, urtikarija Poremećaji metabolizma i prehrane Vrlo često anoreksija (koja može biti teška)
English: Severe stomach pain, nausea, vomiting of blood, black or bloody stools (possible symptoms of gastrointestinal perforation).
Croatian: Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka) - Jaka bol u trbuhu, mučnina, povraćanje krvi, crne ili krvave stolice (mogući simptomi puknuća stijenke u probavnom traktu).
English: Hepatobiliary disorders
Croatian: Trombocitopenija
English: Monotherapy (ovarian and small cell lung carcinoma) There is insufficient experience with the use of topotecan in patients with severely impaired renal function (creatinine clearance <20 ml/min).
Croatian: Nema dovoljno iskustva s primjenom topotekana u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina < 20 ml/min).
English: How Topotecan Teva is given
Croatian: Kako se primjenjuje Topotekan Teva
English: Pancytopenia
Croatian: cisplatin
English: However, caution should be observed when driving or operating machines if fatigue and asthenia persist.
Croatian: ukoliko su trajno prisutni umor i astenija, preporučuje se oprez prilikom vožnje i rada sa strojevima.
English: Anaphylactic reaction, angioedema, urticaria
Croatian: Poremećaji jetre i žuči
English: Tel: +421 2 5726 7911
Croatian: Teva Pharmaceuticals Slovakia s.r.o. Tel: + 421 2 5726 7911
English: Mucosal inflammation
Croatian: Prijavljivanje nuspojava
English: The following information is intended for healthcare professionals only: Instructions on how to dilute, store and dispose of Topotecan Teva Instructions for dilution
Croatian: Upute za razrjeđivanje, čuvanje i odlaganje lijeka Topotekan Teva Upute za razrjeđivanje
English: Myelosuppression leading to sepsis and fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.8).
Croatian: U bolesnika liječenih topotekanom prijavljena je mijelosupresija koja je dovela do sepse i smrtnog ishoda uslijed sepse (vidjeti dio 4.8).
English: For cervical cancer it will be used together with another anticancer medicine containing cisplatin.
Croatian: U liječenju raka vrata maternice Topotekan Teva se kombinira s drugim lijekom koji sadrži cisplatin.
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: Tel.: +48 22 345 93 00
Croatian: Teva Pharmaceuticals Polska Sp. z o.o. Tel.: + 48 22 345 93 00
English: Tel: +351 21 476 75 50
Croatian: Teva Pharma - Produtos Farmacêuticos Lda Tel: +351 21 476 75 50
English: Open date:________
Croatian: Datum otvaranja:________
English: After opening: Use within 2 months.
Croatian: Nakon otvaranja: Upotrijebiti unutar 2 mjeseca.
English: After opening:
Croatian: Nakon otvaranja:
English: After first opening of the bottle, the medicinal product should be used within 2 months.
Croatian: Nakon prvog otvaranja boce, lijek se mora upotrijebiti u roku od 2 mjeseca.
English: If you take more Clopidogrel BGR than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Croatian: Ako uzmete više Clopidogrel BGRa nego što ste trebali Odmah morate kontaktirati liječnika ili najbliži odjel hitne medicinske pomoći zbog povećanog rizika od krvarenja.
English: Blister (OPA/Alu/PVC-Alu) 3 years.
Croatian: Blister (OPA/Al/PVC-Al) 3 godine.
English: Do not use this medicine after the expiry date which is stated on the packaging after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju nakon "EXP".
English: Date of first authorisation: 21 September 2009 Date of latest renewal: 8 May 2014
Croatian: Datum posljednje obnove odobrenja: 08. svibnja 2014.
English: Clopidogrel BGR with food and drink Clopidogrel BGR may be taken with or without food.
Croatian: Clopidogrel BGR s hranom i pićem Clopidogrel BGR se može uzimati s obrokom ili bez obroka.
English: HDPE bottle
Croatian: HDPE boca
English: Some other medicines may influence the use of Clopidogrel BGR or vice versa.
Croatian: Neki lijekovi mogu utjecati na djelovanje Clopidogrel BGRa i obratno.
English: Blister (OPA/Alu/PVC-Alu)
Croatian: Blister (OPA/Al/PVC-Al)
English: (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Croatian: Njihova je učestalost definirana na sljedeći način: česte (≥1/100 i <1/10); manje česte (≥1/1000 i <1/100); rijetke (≥1/10 000 i <1/1000); vrlo rijetke (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
English: You should take Clopidogrel BGR for as long as your doctor continues to prescribe it.
Croatian: Clopidogrel BGR trebate uzimati sve dok Vam ga liječnik propisuje.
English: For bottle
Croatian: Za bocu
English: CARTON/for blisters and bottle
Croatian: KUTIJA/za blistere i bocu
English: Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Croatian: Bolesnici s rijetkim nasljednim poremećajima nepodnošenja galaktoze, potpunim nedostatkom laktaze ili malapsorpcijom glukoze i galaktoze ne bi smjeli uzimati ovaj lijek.
English: LABEL FOR BOTTLE
Croatian: NALJEPNICA ZA BOCU
English: Boxes of 30 and 500 film-coated tablets in bottles are available.
Croatian: Dostupne su kutije s 30 i 500 filmom obloženih tableta u bocama.
English: You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel BGR and acetylsalicylic acid for this condition.
Croatian: Trebalo Vam je biti rečeno da su za ovo stanje 'oralni antikoagulansi' učinkovitiji od acetilsalicilatne kiseline ili kombinirane primjene Clopidogrela BGR i acetilsalicilatne kiseline.
English: As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel BGR.
Croatian: Kao mjera opreza, treba prestati s dojenjem za vrijeme liječenja Clopidogrel BGRom.
English: Your doctor should have prescribed Clopidogrel BGR plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
Croatian: Liječnik Vam treba propisati Clopidogrel BGR i acetilsalicilatnu kiselinu ako ne možete uzimati oralne antikoagulanse te nemate rizik od velikog krvarenja.
English: If you forget to take a dose of Clopidogrel BGR, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Croatian: Ako zaboravite uzeti jednu dozu Clopidogrel BGRa, ali se toga sjetite u roku od 12 sati, odmah uzmite tabletu, a sljedeću tabletu uzmite u uobičajeno vrijeme.
English: Clopidogrel BGR contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
Croatian: Clopidogrel BGR sadrži klopidogrel i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
English: For blister
Croatian: Za blister
English: What Clopidogrel BGR looks like and contents of the pack The film-coated tablets are pink, round and slightly convex.
Croatian: Kako Clopidogrel BGR izgleda i sadržaj pakiranja Filmom obložene tablete su ružičaste, okrugle i blago konveksne.
English: What Clopidogrel BGR is and what it is used for
Croatian: Što je Clopidogrel BGR i za što se koristi